Andrew Cherniack

基本信息

Career Trajectory

Bio

My group at the Broad and Dana-Farber is involved in three different efforts:
1) Along with Dr. Rameen Beroukhim, we lead efforts to analyze copy number alterations and rearrangements for the National Cancer Institute’s Genomic Data Analysis Network (GDAN).
2) We provide computational biology support for new target discovery and biomarker development for cancer therapeutics projects at the Broad Institute.
3) We collaborate with physicians and scientists across Dana-Farber on research projects utilizing clinical targeted sequencing data.

Research Interests

Papers共 365 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Protocol for Assessing Distances in Pathway Space for Classifier Feature Sets from Machine Learning Methods

Bahar Tercan, Victor H Apolonio, Vinicius S Chagas, Christopher K Wong, Jordan A Lee,Christina Yau,Christopher C Benz,Joshua M Stuart, Brian J Karlberg,Kyle Ellrott, Jasleen K Grewal,Steven J M Jones, Cancer Genome Atlas Analysis Network,Jean C Zenklusen,A Gordon Robertson,Peter W Laird,Andrew D Cherniack, A

STAR protocolsno. 2 (2025): 103681-103681

Cited0Views0WOSBibtex

Molecular Characterization of HER2-negative Breast Cancers Reveals a Distinct Patient Subgroup with 17q12 Deletion and Heterozygous Loss of ERBB2

X. Qiu,P. Tarantino, R. Li,A. Grinshpun, H. Gupta,M. E. Hughes, G. Kirkner, L. Scholl, B. E. Johnson, M. Meyerson,A. D. Cherniack, Y. Jiang, N. Zhou,N. U. Lin, H. W. Long,S. M. Tolaney,R. Jeselsohn

ESMO OPEN（2025）

Cited0Views0WOSBibtex

A Phase I Trial of Trebananib, an Angiopoietin 1 and 2 Neutralizing Peptibody, Combined with Pembrolizumab in Patients with Advanced Ovarian and Colorectal Cancer

CANCER IMMUNOLOGY RESEARCHno. 1 (2025): 9-22

Cited0Views0WOSBibtex

Supplementary Figure 3 from ras/raf Comutation and erbb2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

openalex

Cited0Views0Bibtex

Supplementary Figure 4 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Abstract PO1-14-10: Comprehensive Clinicogenomic Characterization of Inflammatory Breast Cancer

Cancer Researchno. 9_Supplement (2024): PO1-14

Cited0Views0Bibtex

Predictors of Exceptional Response to First Line HER2-targeted Therapy for Metastatic Breast Cancer

Stefania Morganti,Tianyu Li,Katheryn Santos,Melissa Hughes,Nolan Priedigkeit,Yvonne Li,Marla Lipsyc-Sharf,Gregory Kirkner,Janet Files,Julie Kasparian, Elizabeth Grant, Gunjan Gupta,Giuseppe Curigliano,Sara Tolaney,Andrew Cherniack,Nabihah Tayob,Nancy Lin,Heather Parsons

CANCER RESEARCHno. 9 (2024)

Cited0Views0Bibtex

Supplementary Table 9 from RAS/RAF Comutation and ERBB2 Copy Number Modulates HER2 Heterogeneity and Responsiveness to HER2-directed Therapy in Colorectal Cancer

crossref（2024）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn

Group Leader

Papers共 365 篇Author StatisticsCo-AuthorSimilar Experts